Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Pretty weak financial results growth rate 8.9% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-1.5%)
  • Dividend yield for the last twelve months 1.8%
  • Free cash flow yield 0.8% (LTM)
  • Share price is 44.8% higher than minimum and 6.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (25.6x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+1.0%)130.59
year average price 128.00  


year start price 115.90 2024-11-16

min close price 111.10 2025-01-15

max close price 140.22 2025-03-03

current price 130.59 2025-11-15
Common stocks: 1 746 881 140

Dividend Yield:  1.8%
FCF Yield LTM: 0.8%
EV / LTM EBITDA: 25.6x
EV / EBITDA annualized: 24.1x
Last revenue growth (y/y):  +6.9%
Last growth of EBITDA (y/y):  +10.9%
Historical revenue growth:  -0.5%
Historical growth of EBITDA:  -2.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 228 125
Net Debt ($m): 5 564
EV (Enterprise Value): 233 689
EBITDA LTM ($m): 9 119
EV / LTM EBITDA: 25.6x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-14zacks.com

Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?

2025-11-13247wallst.com

Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas

2025-10-26247wallst.com

Goldman Sachs Still Says Sell-Off Coming – 5 Safe Conviction List Picks

2025-10-17247wallst.com

Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth

2025-10-15seekingalpha.com

Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript

2025-10-15zacks.com

Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs

2025-10-15zacks.com

Abbott (ABT) Q3 Earnings Meet Estimates

2025-10-15reuters.com

Abbott posts higher quarterly revenue on strong medical device demand

2025-10-12seekingalpha.com

Wall Street Week Ahead

2025-10-10zacks.com

Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data